Statement: 1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma.
Primary_evidence: Adverse Events 1:   Total: 2/60 (3.33%)   Bronchial infection 0/60 (0.00%)   Ankle fracture 1/60 (1.67%)   Clear cell kidney cancer 0/60 (0.00%)   Programmed peritoneal dialysis 1/60 (1.67%)   Endometrial atrophy 0/60 (0.00%) Adverse Events 2:   Total: 3/58 (5.17%)   Bronchial infection 1/58 (1.72%)   Ankle fracture 0/58 (0.00%)   Clear cell kidney cancer 1/58 (1.72%)   Programmed peritoneal dialysis 0/58 (0.00%)   Endometrial atrophy 1/58 (1.72%)